Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment

Area of Science:

• Oncology
• Pharmacology

Background:

• Afatinib is an irreversible ErbB family blocker for metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations.
• It is also used for metastatic squamous NSCLC after platinum-based chemotherapy.
• Gastrointestinal and dermatologic toxicities are common and can limit afatinib dosage.

Purpose of the Study:

• To review clinical trial experiences with afatinib.
• To describe best practices for managing afatinib-associated adverse events.
• To provide practical approaches for EGFR mutation-positive NSCLC patients.

Main Methods:

• Review of safety and tolerability data from phase 3 afatinib trials.
• Inclusion of real-life clinical experiences from authors' practices.

Main Results:

• Patient education is crucial for managing afatinib toxicity.
• Early assessment and effective management of adverse events are vital.
• Dose-reduction strategies enable continued treatment and maximized clinical benefits.

Conclusions:

• Proactive management of afatinib-associated adverse events is essential.
• Strategies including patient education and dose adjustments improve treatment adherence.
• Effective toxicity management allows patients to sustain afatinib therapy for optimal outcomes in NSCLC.